Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The value of circulating microRNAs for early diagnosis of B-cell lymphoma: A case-control study on historical samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. LATER TREATMENT AND EARLIER DIAGNOSIS OF DEL(17P) CLL AFTER INTRODUCTION OF TARGETED THERAPIES

    Publikation: KonferencebidragPosterForskningpeer review

  • Joachim Baech
  • Steen Moeller Hansen
  • Lasse Hjort Jakobsen
  • Andreas K Øvlisen
  • Marianne Tang Severinsen
  • Peter de Nully Brown
  • Peter Vestergaard
  • Henrik Frederiksen
  • Judit Jørgensen
  • Jørn Starklint
  • Pär Josefsson
  • Troels Hammer
  • Michael Roost Clausen
  • Christian Torp-Pedersen
  • Paw Jensen
  • Tarec Christoffer El-Galaly
Vis graf over relationer

High-dose prednisolone is used in first-line treatment for lymphoma, but the potential adverse impact on bone health is unclear. Danish patients with diffuse large B-cell lymphoma or follicular lymphoma diagnosed between 2000 and 2012 were matched to the background population. Osteoporotic events (osteoporosis treatment or low-energy fracture) were identified using the Danish National Patient Registry and Prescription Registry. In total, 2589 patients and 12,945 controls were included. Lymphoma patients had increased risk of osteoporotic events compared to the matched population (hazard ratio 1.61 [95% confidence interval 1.40;1.84]). The 5- and 10-year cumulative risks of osteoporotic events for lymphoma patients were 10.0% [8.6;11.4] and 16.3% [13.8;18.7], whereas corresponding risks in the background population were 6.8% [6.3;7.3] and 13.5% [12.4;14.6]. Patients without osteoporotic event in the first two years after treatment were not at higher risk of osteoporotic events in subsequent years. Risk factors for osteoporotic events were female sex and age >70 years.

OriginalsprogEngelsk
TidsskriftLeukemia and Lymphoma
Vol/bind61
Udgave nummer6
Sider (fra-til)1345-1354
Antal sider10
ISSN1042-8194
DOI
StatusUdgivet - jun. 2020

ID: 59291454